Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion
Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Spinal Fusion Acquired; Spinal Stenosis; Lesions of Lumbosacral Intervertebral Disc; Spinal Diseases
Intervention: Intravenous infusion of Dexmedetomidine or 0.9% Saline (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Vanderbilt University Official(s) and/or principal investigator(s): James L Blair, DO, Principal Investigator, Affiliation: Vanderbilt University
Summary
Major lumbar spine surgery causes inflammation, soreness and swelling that can delay
discharge from the hospital. Dexmedetomidine (DEX) has been shown to have anti-inflammatory
effects. This study will evaluate whether DEX can help get patients out of the hospital
faster after major spine surgery by reducing the inflammation associated with the procedure
itself. A separate part of the study will evaluate the blood levels of some specific
indicators of inflammation called cytokines. Measuring cytokines before and after surgery
will aid in determining if DEX has altered the inflammatory response.
Clinical Details
Official title: Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Time required after surgery to reach fitness for discharge from hospital
Detailed description:
Inflammation is a two-edged sword, one edge essential for healing, the other potentially
delaying recovery. There is evidence that modest attenuation of the initial course of the
inflammatory response (IR) - essentially "banking the fire" of the early IR - may be of
benefit in shortening overall hospital course. Several medications have been
evaluated/utilized intra- and perioperatively to modulate different components of IR,
including local anesthetics, steroids and non-steroidal drugs. Additionally, the pro-and
anti-inflammatory properties of various alpha- and beta-adrenergic agonists and antagonists
have been characterized. Of this last category, dexmedetomidine (DEX), a highly specific
ligand for all the subtypes of the alpha-2 receptor throughout the body, has substantial
potency for sedation, analgesia and a reduction in the stress response in a wide variety of
surgical environments as well as contributing to cardiovascular stability during CABG and
open craniotomy. Additionally, DEX has been shown to have quite powerful anti-inflammatory
activity in a murine endotoxin model. DEX's anti-inflammatory activity is likely expressed
at G protein-coupled receptors (GPCRs) - either conformationally similar to, or the actual
"native" alpha-2 receptor - on polymorphonuclear leukocytes, tissue macrophages, mast cells
and other immune system cells. Through these receptors, DEX may attenuate the early phase of
IR by limiting immune signaling or release of inflammatory cytokines, potentially favorably
limiting the body's IR to injury.
In this present study, our primary assumption is that an ordinarily exuberant IR would be
invoked by major spine fusion surgery. Continuous administration of intravenous DEX during
and immediately after surgery might sufficiently modulate the IR to shorten hospital stay.
Therefore, in a prospective, randomized, placebo-controlled, double blinded fashion, we plan
to evaluate the potential for a perioperative infusion of DEX to reduce
"time-to-fitness-for-discharge" (generally easier to mark and a more accurate surrogate of
time-to-discharge) in patients undergoing major 3+ level lumbar spinal fusion procedures.
Additionally, cytokine markers, pain scores and additional pain medication requirements
associated with surgery will be measured.
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA Classification I - III
- Scheduled for Open Posterior Lumbar Fusion over 3+ (bony) levels
Exclusion Criteria:
- Allergy to dexmedetomidine
- Cardiac disease with reduced ejection fraction < 30%
- History of cirrhosis, active hepatitis or attenuated hepatic function
- Chronic use of steroids, COX-2 inhibitors, alpha-2 agonists, or statins
- Current anticoagulant therapy
- Patients requiring motor evoked potential (MEP) monitoring
- Positive pregnancy test
Locations and Contacts
Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
Additional Information
Related publications: Taniguchi T, Kurita A, Kobayashi K, Yamamoto K, Inaba H. Dose- and time-related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats. J Anesth. 2008;22(3):221-8. doi: 10.1007/s00540-008-0611-9. Epub 2008 Aug 7. Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007 Jan;8(1):25-33. Review. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004 Oct 11;502(1-2):87-97. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003 Feb;98(2):428-36. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology. 1996 Apr;84(4):873-81.
Starting date: June 2009
Last updated: January 29, 2014
|